Most Recent Annual Report
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
2019 Annual Report and Form 10K
Oyster Point Pharma, Inc. has reached its limit for free report views.
Work for Oyster Point Pharma, Inc.?
Claim Your Profile
Oyster Point Pharma, Inc.
About Oyster Point Pharma, Inc.
11-50 Employees
Based in Princeton, New Jersey
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01 nasal spray’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit (LFU).
- Ticker:
- OYST
- Exchange:
- NASDAQ (See More NASDAQ Companies)
- Industry:
- Biotechnology (See More Biotechnology Companies)
- Sector:
- Healthcare (See More Healthcare Companies)
